David Cotter, MD, PhD, a board-certified dermatologist at Las Vegas Dermatology in Las Vegas, Nevada, discusses a patient case of prurigo nodularis and related trial findings. The patient he treated had over 100 lesions at presentation and had already received multiple lines of therapy previously. Dr. Cotter decided to use nemolizumab (Nemluvio) as the next line of treatment. The patient achieved complete clearance by Week 16 of treatment, which exceeded the 25% to 40% clearance rate seen in clinical trials. He also reviews a clinical trial of nemolizumab and the recommended dosing for this treatment.
